Andreas Kleppe
- Researcher; PhD
Publications 2024
DNA ploidy and PTEN as biomarkers for predicting aggressive disease in prostate cancer patients under active surveillance
Br J Cancer, 131 (5), 895-904
DOI 10.1038/s41416-024-02780-x, PubMed 38961192
Prognostic and therapeutic implication of molecular classification including L1CAM expression in high-risk endometrial cancer
Gynecol Oncol, 192, 80-88 (in press)
DOI 10.1016/j.ygyno.2024.11.005, PubMed 39549540
Impact of molecular profile on prognosis and relapse pattern in low and intermediate risk endometrial cancer
Eur J Cancer, 200, 113584
DOI 10.1016/j.ejca.2024.113584, PubMed 38330767
Publications 2023
Patient-reported nausea after implementation of an enhanced recovery after surgery protocol for gynae-oncology patients
Int J Gynecol Cancer, 33 (8), 1287-1294
DOI 10.1136/ijgc-2023-004356, PubMed 37451689
Prospective evaluation of an enhanced recovery after surgery (ERAS) pathway in a Norwegian cohort of patients with suspected or advanced ovarian cancer
Int J Gynecol Cancer, 33 (8), 1279-1286
DOI 10.1136/ijgc-2023-004355, PubMed 37451690
Personalizing adjuvant therapy for patients with colorectal cancer
Nat Rev Clin Oncol, 21 (1), 67-79
DOI 10.1038/s41571-023-00834-2, PubMed 38001356
Publications 2022
A clinical decision support system optimising adjuvant chemotherapy for colorectal cancers by integrating deep learning and pathological staging markers: a development and validation study
Lancet Oncol, 23 (9), 1221-1232
DOI 10.1016/S1470-2045(22)00391-6, PubMed 35964620
Publications 2021
PTEN and DNA Ploidy Status by Machine Learning in Prostate Cancer
Cancers (Basel), 13 (17)
DOI 10.3390/cancers13174291, PubMed 34503100
Designing deep learning studies in cancer diagnostics
Nat Rev Cancer, 21 (3), 199-211
DOI 10.1038/s41568-020-00327-9, PubMed 33514930
Deep learning and cancer biomarkers: recognising lead-time bias - Authors' reply
Lancet, 397 (10270), 194-195
DOI 10.1016/S0140-6736(21)00035-0, PubMed 33453777
Immune checkpoint B7-H3 protein expression is associated with poor outcome and androgen receptor status in prostate cancer
Prostate, 81 (12), 838-848
DOI 10.1002/pros.24180, PubMed 34125445
Long-term oncological outcomes and recurrence patterns in early-stage cervical cancer treated with minimally invasive versus abdominal radical hysterectomy: The Norwegian Radium Hospital experience
Gynecol Oncol, 162 (2), 284-291
DOI 10.1016/j.ygyno.2021.05.028, PubMed 34083029
Publications 2020
Prognostic value of DNA ploidy and automated assessment of stroma fraction in prostate cancer
Int J Cancer, 147 (4), 1228-1234
DOI 10.1002/ijc.32832, PubMed 31846064
Prognostic Value of the Diversity of Nuclear Chromatin Compartments in Gynaecological Carcinomas
Cancers (Basel), 12 (12)
DOI 10.3390/cancers12123838, PubMed 33352679
Deep learning for prediction of colorectal cancer outcome: a discovery and validation study
Lancet, 395 (10221), 350-360
DOI 10.1016/S0140-6736(19)32998-8, PubMed 32007170
Publications 2019
Prognostic value of mitotic checkpoint protein BUB3, cyclin B1, and pituitary tumor-transforming 1 expression in prostate cancer
Mod Pathol, 33 (5), 905-915
DOI 10.1038/s41379-019-0418-2, PubMed 31801961
Publications 2018
Chromatin organisation and cancer prognosis: a pan-cancer study
Lancet Oncol, 19 (3), 356-369
DOI 10.1016/S1470-2045(17)30899-9, PubMed 29402700
Clinical utility of chromatin analysis
Oncotarget, 9 (65), 32406-32407
DOI 10.18632/oncotarget.25991, PubMed 30197751
Association Between Proportion of Nuclei With High Chromatin Entropy and Prognosis in Gynecological Cancers
J Natl Cancer Inst, 110 (12), 1400-1408
DOI 10.1093/jnci/djy063, PubMed 29684152
Publications 2017
Tumour heterogeneity poses a significant challenge to cancer biomarker research
Br J Cancer, 117 (3), 367-375
DOI 10.1038/bjc.2017.171, PubMed 28618431
Publications 2016
Chromatin changes predict recurrence after radical prostatectomy
Br J Cancer, 114 (11), 1243-50
DOI 10.1038/bjc.2016.96, PubMed 27124335